Global Biopharma Outsourcing

Biopharma Outsourcing Comprehensive Study by Application (Clinical Trials, Drug Discovery, API Development, Contract Production & Packaging, Non-Clinical Services, Others), Outsourcing Scale (Large Scale, Small Scale, Medium Scale), Activity (Downstream Process Development, Upstream Process Develop men, Design of Experiments (DoE), Quality by Design (QbD)) Players and Region - Global Market Outlook to 2028

Biopharma Outsourcing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Biopharma Outsourcing Market Scope?
The biopharmaceutical industry is changing the way it manufactures. According to BioPlan Associates’ 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, outsourcing and off-shoring have migrated into much more high-value areas of opportunity over the past ten years. The developing regions such as China, India, and Brazil are investing in technologies that improve productivity and efficiency are making outsourcing more strategic.

Influencing Trend:
Majority Of Biosimilars Production Being Outsourced

Market Growth Drivers:
Outsourcing Overcomes Trade Barriers and Increasing Adoption of Outsourcing Biopharma for Manufacturing

Challenges:
Meet Quality Requirement and On-time Delivery

Restraints:
Regulation on Outsourcing of Biopharma Products

Opportunities:
Rise in R&D Outsourcing and Eliminate Need of Hiring and Training Staff Hence Saving Cost of Biopharma Companies

The Biopharma Outsourcing market study is being classified, by Application and major geographies with country level break-up.

Market players in biopharma outsourcing are improving their technical and production capabilities to serve the biopharma industry more efficiently. The outsourcing for production of biopharma products clearly will continue, and become more important as more and smaller companies look for opportunities to enter the market and get their products into clinical trials. This will increase the competitiveness among the service providers of the global biopharma outsourcing market Analysts at AMA predicts that Players from United States, United Kingdom, China will contribute to the maximum growth of Global Biopharma Outsourcing market throughout the predicted period.

Sartorius AG (Germany), Emcure Pharmaceuticals Ltd (India), BioPharma Services Inc. (Canada), Quintiles Inc. (United States), Lonza Group AG (Switzerland), Eurofins Scientific (Luxembourg), Baxter International Inc.(United States), KBI Biopharm Inc. (United States), Chiltern International Ltd. (United Kingdom), GSK plc (United Kingdom) and WuXi Biologics (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Keyrus Biopharma (France), Aptuit LLC (United States), ICON plc (Ireland) and Rentschler Biotechnologie GmbH (Germany).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Biopharma Outsourcing market by Type, Application and Region.

On the basis of geography, the market of Biopharma Outsourcing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In February 2022, Sartorius AG acquired Novasep chromatography division. The portfolio acquired comprises chromatography systems primarily suited for smaller biomolecules, such as oligonucleotides, peptides, and insulin, as well as innovative systems for continuous manufacturing of biologics.
In April 2022, Boehringer Ingelheim increases its R&D commitment and anticipates up to 15 new product launches by 2025. It spent nearly USD 4.5 billion (20 percent of net sales) on R&D last year, putting it just behind some of the top spenders in the pharmaceutical industry. It also intends to invest more than USD 27 billion in drug development over the next five years.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Biopharma Outsourcing Providers, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms and Government Regulatory and Research Organizations

Biopharma Outsourcing Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Analyst View
Research Says, "As countries and companies alike continue to grapple with the unprecedented challenges thrown up by the novel coronavirus (COVID-19), the concern of uncertainty surrounding the impact of the COVID-19 pandemic on the global biopharma outsourcing market has risen. The lockdown in several countries majorly in China as it accounts for nearly 65-70% of supply chain industry has majorly effected the growth of global biopharma outsourcing market."

Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Biopharma Outsourcing Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Biopharma Outsourcing industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Application
  • Clinical Trials
  • Drug Discovery
  • API Development
  • Contract Production & Packaging
  • Non-Clinical Services
  • Others
By Outsourcing Scale
  • Large Scale
  • Small Scale
  • Medium Scale

By Activity
  • Downstream Process Development
  • Upstream Process Develop men
  • Design of Experiments (DoE)
  • Quality by Design (QbD)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Outsourcing Overcomes Trade Barriers
      • 3.2.2. Increasing Adoption of Outsourcing Biopharma for Manufacturing
    • 3.3. Market Challenges
      • 3.3.1. Meet Quality Requirement and On-time Delivery
    • 3.4. Market Trends
      • 3.4.1. Majority Of Biosimilars Production Being Outsourced
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biopharma Outsourcing, by Application, Outsourcing Scale, Activity and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Biopharma Outsourcing (Value)
      • 5.2.1. Global Biopharma Outsourcing by: Application (Value)
        • 5.2.1.1. Clinical Trials
        • 5.2.1.2. Drug Discovery
        • 5.2.1.3. API Development
        • 5.2.1.4. Contract Production & Packaging
        • 5.2.1.5. Non-Clinical Services
        • 5.2.1.6. Others
      • 5.2.2. Global Biopharma Outsourcing by: Outsourcing Scale (Value)
        • 5.2.2.1. Large Scale
        • 5.2.2.2. Small Scale
        • 5.2.2.3. Medium Scale
      • 5.2.3. Global Biopharma Outsourcing by: Activity (Value)
        • 5.2.3.1. Downstream Process Development
        • 5.2.3.2. Upstream Process Develop men
        • 5.2.3.3. Design of Experiments (DoE)
        • 5.2.3.4. Quality by Design (QbD)
      • 5.2.4. Global Biopharma Outsourcing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Biopharma Outsourcing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sartorius AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Emcure Pharmaceuticals Ltd (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioPharma Services Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Quintiles Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lonza Group AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eurofins Scientific (Luxembourg)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Baxter International Inc.(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. KBI Biopharm Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Chiltern International Ltd. (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GSK plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. WuXi Biologics (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Biopharma Outsourcing Sale, by Application, Outsourcing Scale, Activity and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Biopharma Outsourcing (Value)
      • 7.2.1. Global Biopharma Outsourcing by: Application (Value)
        • 7.2.1.1. Clinical Trials
        • 7.2.1.2. Drug Discovery
        • 7.2.1.3. API Development
        • 7.2.1.4. Contract Production & Packaging
        • 7.2.1.5. Non-Clinical Services
        • 7.2.1.6. Others
      • 7.2.2. Global Biopharma Outsourcing by: Outsourcing Scale (Value)
        • 7.2.2.1. Large Scale
        • 7.2.2.2. Small Scale
        • 7.2.2.3. Medium Scale
      • 7.2.3. Global Biopharma Outsourcing by: Activity (Value)
        • 7.2.3.1. Downstream Process Development
        • 7.2.3.2. Upstream Process Develop men
        • 7.2.3.3. Design of Experiments (DoE)
        • 7.2.3.4. Quality by Design (QbD)
      • 7.2.4. Global Biopharma Outsourcing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biopharma Outsourcing: by Application(USD Million)
  • Table 2. Biopharma Outsourcing Clinical Trials , by Region USD Million (2017-2022)
  • Table 3. Biopharma Outsourcing Drug Discovery , by Region USD Million (2017-2022)
  • Table 4. Biopharma Outsourcing API Development , by Region USD Million (2017-2022)
  • Table 5. Biopharma Outsourcing Contract Production & Packaging , by Region USD Million (2017-2022)
  • Table 6. Biopharma Outsourcing Non-Clinical Services , by Region USD Million (2017-2022)
  • Table 7. Biopharma Outsourcing Others , by Region USD Million (2017-2022)
  • Table 8. Biopharma Outsourcing: by Outsourcing Scale(USD Million)
  • Table 9. Biopharma Outsourcing Large Scale , by Region USD Million (2017-2022)
  • Table 10. Biopharma Outsourcing Small Scale , by Region USD Million (2017-2022)
  • Table 11. Biopharma Outsourcing Medium Scale , by Region USD Million (2017-2022)
  • Table 12. Biopharma Outsourcing: by Activity(USD Million)
  • Table 13. Biopharma Outsourcing Downstream Process Development , by Region USD Million (2017-2022)
  • Table 14. Biopharma Outsourcing Upstream Process Develop men , by Region USD Million (2017-2022)
  • Table 15. Biopharma Outsourcing Design of Experiments (DoE) , by Region USD Million (2017-2022)
  • Table 16. Biopharma Outsourcing Quality by Design (QbD) , by Region USD Million (2017-2022)
  • Table 17. South America Biopharma Outsourcing, by Country USD Million (2017-2022)
  • Table 18. South America Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 19. South America Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 20. South America Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 21. Brazil Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 22. Brazil Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 23. Brazil Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 24. Argentina Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 25. Argentina Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 26. Argentina Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 27. Rest of South America Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 29. Rest of South America Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 30. Asia Pacific Biopharma Outsourcing, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 33. Asia Pacific Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 34. China Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 35. China Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 36. China Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 37. Japan Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 38. Japan Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 39. Japan Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 40. India Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 41. India Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 42. India Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 43. South Korea Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 44. South Korea Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 45. South Korea Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 46. Taiwan Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 47. Taiwan Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 48. Taiwan Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 49. Australia Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 50. Australia Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 51. Australia Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 55. Europe Biopharma Outsourcing, by Country USD Million (2017-2022)
  • Table 56. Europe Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 57. Europe Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 58. Europe Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 59. Germany Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 60. Germany Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 61. Germany Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 62. France Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 63. France Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 64. France Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 65. Italy Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 66. Italy Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 67. Italy Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 68. United Kingdom Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 70. United Kingdom Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 71. Netherlands Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 72. Netherlands Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 73. Netherlands Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 74. Rest of Europe Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 76. Rest of Europe Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 77. MEA Biopharma Outsourcing, by Country USD Million (2017-2022)
  • Table 78. MEA Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 79. MEA Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 80. MEA Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 81. Middle East Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 82. Middle East Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 83. Middle East Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 84. Africa Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 85. Africa Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 86. Africa Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 87. North America Biopharma Outsourcing, by Country USD Million (2017-2022)
  • Table 88. North America Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 89. North America Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 90. North America Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 91. United States Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 92. United States Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 93. United States Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 94. Canada Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 95. Canada Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 96. Canada Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 97. Mexico Biopharma Outsourcing, by Application USD Million (2017-2022)
  • Table 98. Mexico Biopharma Outsourcing, by Outsourcing Scale USD Million (2017-2022)
  • Table 99. Mexico Biopharma Outsourcing, by Activity USD Million (2017-2022)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Biopharma Outsourcing: by Application(USD Million)
  • Table 112. Biopharma Outsourcing Clinical Trials , by Region USD Million (2023-2028)
  • Table 113. Biopharma Outsourcing Drug Discovery , by Region USD Million (2023-2028)
  • Table 114. Biopharma Outsourcing API Development , by Region USD Million (2023-2028)
  • Table 115. Biopharma Outsourcing Contract Production & Packaging , by Region USD Million (2023-2028)
  • Table 116. Biopharma Outsourcing Non-Clinical Services , by Region USD Million (2023-2028)
  • Table 117. Biopharma Outsourcing Others , by Region USD Million (2023-2028)
  • Table 118. Biopharma Outsourcing: by Outsourcing Scale(USD Million)
  • Table 119. Biopharma Outsourcing Large Scale , by Region USD Million (2023-2028)
  • Table 120. Biopharma Outsourcing Small Scale , by Region USD Million (2023-2028)
  • Table 121. Biopharma Outsourcing Medium Scale , by Region USD Million (2023-2028)
  • Table 122. Biopharma Outsourcing: by Activity(USD Million)
  • Table 123. Biopharma Outsourcing Downstream Process Development , by Region USD Million (2023-2028)
  • Table 124. Biopharma Outsourcing Upstream Process Develop men , by Region USD Million (2023-2028)
  • Table 125. Biopharma Outsourcing Design of Experiments (DoE) , by Region USD Million (2023-2028)
  • Table 126. Biopharma Outsourcing Quality by Design (QbD) , by Region USD Million (2023-2028)
  • Table 127. South America Biopharma Outsourcing, by Country USD Million (2023-2028)
  • Table 128. South America Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 129. South America Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 130. South America Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 131. Brazil Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 132. Brazil Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 133. Brazil Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 134. Argentina Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 135. Argentina Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 136. Argentina Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 137. Rest of South America Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 138. Rest of South America Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 139. Rest of South America Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 140. Asia Pacific Biopharma Outsourcing, by Country USD Million (2023-2028)
  • Table 141. Asia Pacific Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 142. Asia Pacific Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 143. Asia Pacific Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 144. China Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 145. China Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 146. China Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 147. Japan Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 148. Japan Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 149. Japan Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 150. India Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 151. India Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 152. India Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 153. South Korea Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 154. South Korea Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 155. South Korea Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 156. Taiwan Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 157. Taiwan Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 158. Taiwan Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 159. Australia Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 160. Australia Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 161. Australia Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 162. Rest of Asia-Pacific Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 163. Rest of Asia-Pacific Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 164. Rest of Asia-Pacific Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 165. Europe Biopharma Outsourcing, by Country USD Million (2023-2028)
  • Table 166. Europe Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 167. Europe Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 168. Europe Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 169. Germany Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 170. Germany Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 171. Germany Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 172. France Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 173. France Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 174. France Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 175. Italy Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 176. Italy Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 177. Italy Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 178. United Kingdom Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 179. United Kingdom Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 180. United Kingdom Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 181. Netherlands Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 182. Netherlands Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 183. Netherlands Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 184. Rest of Europe Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 185. Rest of Europe Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 186. Rest of Europe Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 187. MEA Biopharma Outsourcing, by Country USD Million (2023-2028)
  • Table 188. MEA Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 189. MEA Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 190. MEA Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 191. Middle East Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 192. Middle East Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 193. Middle East Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 194. Africa Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 195. Africa Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 196. Africa Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 197. North America Biopharma Outsourcing, by Country USD Million (2023-2028)
  • Table 198. North America Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 199. North America Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 200. North America Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 201. United States Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 202. United States Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 203. United States Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 204. Canada Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 205. Canada Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 206. Canada Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 207. Mexico Biopharma Outsourcing, by Application USD Million (2023-2028)
  • Table 208. Mexico Biopharma Outsourcing, by Outsourcing Scale USD Million (2023-2028)
  • Table 209. Mexico Biopharma Outsourcing, by Activity USD Million (2023-2028)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biopharma Outsourcing: by Application USD Million (2017-2022)
  • Figure 5. Global Biopharma Outsourcing: by Outsourcing Scale USD Million (2017-2022)
  • Figure 6. Global Biopharma Outsourcing: by Activity USD Million (2017-2022)
  • Figure 7. South America Biopharma Outsourcing Share (%), by Country
  • Figure 8. Asia Pacific Biopharma Outsourcing Share (%), by Country
  • Figure 9. Europe Biopharma Outsourcing Share (%), by Country
  • Figure 10. MEA Biopharma Outsourcing Share (%), by Country
  • Figure 11. North America Biopharma Outsourcing Share (%), by Country
  • Figure 12. Global Biopharma Outsourcing share by Players 2022 (%)
  • Figure 13. Global Biopharma Outsourcing share by Players (Top 3) 2022(%)
  • Figure 14. Global Biopharma Outsourcing share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Sartorius AG (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Sartorius AG (Germany) Revenue: by Geography 2022
  • Figure 18. Emcure Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 19. Emcure Pharmaceuticals Ltd (India) Revenue: by Geography 2022
  • Figure 20. BioPharma Services Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 21. BioPharma Services Inc. (Canada) Revenue: by Geography 2022
  • Figure 22. Quintiles Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Quintiles Inc. (United States) Revenue: by Geography 2022
  • Figure 24. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Lonza Group AG (Switzerland) Revenue: by Geography 2022
  • Figure 26. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 27. Eurofins Scientific (Luxembourg) Revenue: by Geography 2022
  • Figure 28. Baxter International Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 29. Baxter International Inc.(United States) Revenue: by Geography 2022
  • Figure 30. KBI Biopharm Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. KBI Biopharm Inc. (United States) Revenue: by Geography 2022
  • Figure 32. Chiltern International Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Chiltern International Ltd. (United Kingdom) Revenue: by Geography 2022
  • Figure 34. GSK plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. GSK plc (United Kingdom) Revenue: by Geography 2022
  • Figure 36. WuXi Biologics (China) Revenue, Net Income and Gross profit
  • Figure 37. WuXi Biologics (China) Revenue: by Geography 2022
  • Figure 38. Global Biopharma Outsourcing: by Application USD Million (2023-2028)
  • Figure 39. Global Biopharma Outsourcing: by Outsourcing Scale USD Million (2023-2028)
  • Figure 40. Global Biopharma Outsourcing: by Activity USD Million (2023-2028)
  • Figure 41. South America Biopharma Outsourcing Share (%), by Country
  • Figure 42. Asia Pacific Biopharma Outsourcing Share (%), by Country
  • Figure 43. Europe Biopharma Outsourcing Share (%), by Country
  • Figure 44. MEA Biopharma Outsourcing Share (%), by Country
  • Figure 45. North America Biopharma Outsourcing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sartorius AG (Germany)
  • Emcure Pharmaceuticals Ltd (India)
  • BioPharma Services Inc. (Canada)
  • Quintiles Inc. (United States)
  • Lonza Group AG (Switzerland)
  • Eurofins Scientific (Luxembourg)
  • Baxter International Inc.(United States)
  • KBI Biopharm Inc. (United States)
  • Chiltern International Ltd. (United Kingdom)
  • GSK plc (United Kingdom)
  • WuXi Biologics (China)
Additional players considered in the study are as follows:
Keyrus Biopharma (France) , Aptuit LLC (United States) , ICON plc (Ireland) , Rentschler Biotechnologie GmbH (Germany)
Select User Access Type

Key Highlights of Report


Nov 2023 144 Pages 90 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biopharma Outsourcing Quantitative research analysis
Global Biopharma Outsourcing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Biopharma Outsourcing market are Sartorius AG (Germany), Emcure Pharmaceuticals Ltd (India), BioPharma Services Inc. (Canada), Quintiles Inc. (United States), Lonza Group AG (Switzerland), Eurofins Scientific (Luxembourg), Baxter International Inc.(United States), KBI Biopharm Inc. (United States), Chiltern International Ltd. (United Kingdom), GSK plc (United Kingdom) and WuXi Biologics (China).
In this highly competitive & fast evolving Biopharma Outsourcing industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Clinical Trials, Drug Discovery, API Development, Contract Production & Packaging, Non-Clinical Services and Others are the potential customers of Biopharma Outsourcing industry.

Know More About Global Biopharma Outsourcing Report?

Have a Query? Click Here

Other Related Reports

Bronchodilator Comprehensive Study by Type (Short-acting Bronchodilator, Long-acting Bronchodilator), Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Reactions, Others), Drug Cl...
$ 3750
Acne Vulgaris Comprehensive Study by Application (Hospitals, Clinics, Others), Therapy Type (Systemic Therapy, Harmonal Therapy, Topical Combination Therapy, Others), Type of Lesions (Non inflammator...
$ 3500
Myasthenia Gravis Comprehensive Study by Type (Congenital Hereditary, Autoimmune Disease), Application (Hospital, Medical Clinical Research Center, Others), Treatment type (Therapeutic approach, Medi...
$ 3750
Transdermal Skin Patches Comprehensive Study by Type (Drug in Adhesive, Matrix, Reservoir, Vapor, Other), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Use (Hospital Ph...
$ 3450
Kidney Cancer Drugs Comprehensive Study by Type (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus)...
$ 3650
Obesity Treatment Comprehensive Study by Application (Children, Adults), Drugs (Combination Drugs, Appetite Suppressants, Malabsorption, Satiety), Treatment (Medication, Surgery, Lifestyle Changes), ...
$ 3750